Organization (Industry)
Shijiazhuang Yiling Pharmaceutical (China)
ClinicalTrials.gov lists Shijiazhuang Yiling Pharmaceutical (China) as lead sponsor of 13 trials. It has 10 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Shijiazhuang Yiling Pharmaceutical (China): 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 4 |
| Ischemic Stroke | 2 |
| Stroke | 2 |
| Cognitive Dysfunction | 1 |
| Diabetes Mellitus | 1 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2014 | 1 |
Prediction, not a registry value: median of 33 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; 1 of 5 predicted trials reach the 36-month horizon; registered median of 6 months across 7 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (10)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Felbinac Trometamol Injection | Pain | Phase 3 | 4 |
| XY03-EA 300 mg (Regimen A) | Ischemic Stroke | Phase 2 | 1 |
| XY03-EA 300 mg (Regimen A) | Stroke | Phase 2 | 1 |
| XY03-EA 450 mg (per dose) | Ischemic Stroke | Phase 2 | 1 |
| XY03-EA 450 mg (per dose) | Stroke | Phase 2 | 1 |
Showing 5 of 10 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| Moxifloxacin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 83% hit target (n=6) | 40% on time (n=5) |
Journals published in (6)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of neurology | 1 |
| Gastroenterology | 1 |
| Molecular cancer therapeutics | 1 |
| Neurology | 1 |
| Pediatric neurology | 1 |
Showing 5 of 6 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 10 | 5 | 2024-01-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 66 | 2023-05-09 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical Co. Ltd. | Shijiazhuang City, CN | Health Canada |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Peking Union Medical College Hospital | Co sponsors trial with | 1 |
| Xuanwu Hospital, Beijing | Co sponsors trial with | 1 |
| Shanghai Jiao Tong University School of Medicine | Co sponsors trial with | 1 |
Latest dated events (92)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-07-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-01-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-07-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 92 events.
Biomarker capability evidence (46)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CLDN18 | Trial sponsor | Named in trial inclusion criteria |
| F2 | Trial sponsor | Named in trial inclusion criteria |
| FLT3 | Trial sponsor | Named in trial inclusion criteria |
| PCMT1 | Trial sponsor | Named in trial inclusion criteria |
| SLC12A3 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 46 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.